. 2024 Apr 4;19:44. doi: 10.1186/s13014-024-02430-9

Table 3.

Functional tumor volumes (FTVs)

FTV	FAPI-46/dual-tracer PET/CT (ml, mean ± SD)	FDG-PET/CT (ml, mean ± SD)	Wilcoxon signed-rank test; Pearson’s correlation
FTV_total	77.04 ± 84.03	58.09 ± 76.20	p < 0.001; r = 0. 0837
FTV_tumor	49.17 ± 63.67	32.82 ± 49.71	p = 0.002; r = 0.703
FTV_metastases	33.69 ± 74.64	40.03 ± 82.03	p = 0.008; r = 0.992

FTV

FAPI-46/dual-tracer PET/CT (ml, mean ± SD)

FDG-PET/CT
(ml, mean ± SD)

Wilcoxon signed-rank test; Pearson’s correlation

FTV_total

77.04 ± 84.03

58.09 ± 76.20

p < 0.001;

r = 0. 0837

FTV_tumor

49.17 ± 63.67

32.82 ± 49.71

p = 0.002;

r = 0.703

FTV_metastases

33.69 ± 74.64

40.03 ± 82.03

p = 0.008;

r = 0.992

Functional tumor volume (FTV) of all tumorous lesions (FTV_total), tumor (FTV_tumor), and metastasis (FTV_metastases) on FAPI-46/dual-tracer PET/CT and FDG-PET/CT for all patients. Volumes were compared using the Wilcoxon signed-rank test (Pearson’s correlation). FDG = fluorodeoxy-D-glucose, FAPI = fibroblast activation protein inhibitor